Taskin Support for the Specialized Symposium on “Oncolytic Virus Engineering for Cancer Treatment”
On April 21, 2025, a specialized symposium titled “Oncolytic Virus Engineering for Cancer Treatment” was held by the Iranian Immunology […]
Breaking News
Taskin at the 14th Hematopoietic Stem Cell Transplantation Congress & 1st National Hematology Congress 2025
Taskin BioRegeneration, as one of the pioneers in the field of cell therapy, had an active and impactful presence at
Taskin BioRegeneration proudly sponsored and participated in the 4th IranBio International Congress and Exhibition 2025
Taskin BioRegeneration actively participated as one of the sponsors of the 4th IranBio International Congress and Exhibition of Medical Biotechnology
FDA Approves First MSC Therapy for SR-aGVHD: A Milestone in Cell Therapy
The U.S. Food and Drug Administration (FDA) has announced the historic approval of Ryoncil (remestemcel-L-rknd) as the first mesenchymal stromal
Launch of DestroCell in Tehran Marks a New Era in Cell Therapy for Iran and Beyond
On Thursday morning, October 24, 2024, doctors, researchers, and other distinguished guests gathered at Tehran’s Spinas Palace Hotel for the
Taskin Bioregeneration Announces Launch of Phase II/III Clinical Trials for DesRep
Tehran, October 2024 – Taskin Bioregeneration, a pioneering company in regenerative medicine and cell therapy, is proud to announce the
Job Opportunity – Researcher Positions at Taskin Bioregeneration
Taskin Bioregeneration is a leading company in the field of cell and gene therapy. We are currently conducting clinical trials
DestroCell Offers New Hope for Steroid-Resistant GVHD Treatment
Tehran, Iran – September 13, 2024 — In a significant breakthrough for cell therapy and regenerative medicine, Taskin Bioregeneration Co.